Login
$BVS
$10.46 -$0.20 (1.88%) Live

$BVS SEC Filings

Filed On Filing
13 Nov 2026 SCHEDULE 13G
02 Nov 2026 10-Q
02 Nov 2026 8-K: Results of Operations and Financial Condition

DURHAM, NC – November 2, 2026 – Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today reported financial results for the three and nine months ended September 26, 2026.

27 Oct 2026 SCHEDULE 13G/A
05 Aug 2026 10-Q
05 Aug 2026 8-K: Results of Operations and Financial Condition; Other Events

DURHAM, NC – August 5, 2026 – Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today reported financial results for the three and six months ended June 27, 2026.

27 Jul 2026 SCHEDULE 13G
04 Jun 2026 Form 4: Bartholdson John A., Director

Received 32,282 shares by exercise or conversion · Granted 25,146 Restricted Stock Units

04 Jun 2026 Form 4: Sutter Martin P, Director

Received 32,282 shares by exercise or conversion · Granted 25,146 Restricted Stock Units

04 Jun 2026 Form 4: Stalnecker Susan M, Director

Received 32,282 shares by exercise or conversion · Granted 25,146 Restricted Stock Units

04 Jun 2026 Form 4: Nohra Guy P, Director

Received 32,282 shares by exercise or conversion · Granted 25,146 Restricted Stock Units

04 Jun 2026 Form 4: Neels Guido J, Director

Received 32,282 shares by exercise or conversion · Granted 25,146 Restricted Stock Units

04 Jun 2026 Form 4: McMurry-Heath Michelle, Director

Received 32,282 shares by exercise or conversion · Granted 25,146 Restricted Stock Units

04 Jun 2026 Form 4: Ladone Mary Kay, Director

Received 32,282 shares by exercise or conversion · Granted 25,146 Restricted Stock Units

04 Jun 2026 Form 4: Hawkins William A, Director

Received 39,789 shares by exercise or conversion · Granted 30,994 Restricted Stock Units

04 Jun 2026 Form 4: Cowdy Philip G., Director

Received 32,282 shares by exercise or conversion · Granted 25,146 Restricted Stock Units

04 Jun 2026 Form 4: Beyer Pat, Director

Received 32,282 shares by exercise or conversion · Granted 25,146 Restricted Stock Units

04 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

Bioventus, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) on June 3, 2026. A total of 75,279,174 shares (the “Shares”) of both Class A common stock and Class B common stock (collectively, th...

29 May 2026 SD
21 May 2026 8-K: Regulation FD Disclosure

On April 16, 2026, the U.S. Food and Drug Administration (“FDA”) issued a final order reclassifying non-invasive bone growth stimulators, including the Company’s Exogen® Ultrasound Bone Healing System, from Class III to Class II devices....

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support